Gevokizumab

立即咨询

Gevokizumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1129435-60-4

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品介绍

Gevokizumab 是一种有效的抗IL-1β抗体，通过变构机制负向调节IL-1β信号。Gevokizumab 降低IL-1β对 IL-1 受体 I 型 (IL-1RI) 信号受体的结合亲和力，而不影响 IL-1 反调节诱饵受体 (IL-1 受体 II 型)。

生物活性

Gevokizumab is a potent anti-IL-1βantibody, negatively modulatesIL-1βsignaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity ofIL-1βfor theIL-1 receptortype I (IL-1RI) signaling receptor instead ofIL-1counter-regulatorydecoy receptor(IL-1 receptor type II)^[1]^[2].

体外研究
(In Vitro)

Gevokizumab (5 nM; 16 h) shows inhibitory effects of IL-1β-mediated NF-kB activation caused by the soluble receptors, sIL-1RI and sIL-1RII in HeLa cells^[1].
Gevokizumab (1.85, 5.55, 16.66, and 50 nM) is a selective negative allosteric modulator which reduces the binding affinity of sIL-1RI to IL-1β^[1].

体内研究
(In Vivo)

Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation^[2].

Animal Model:	Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g)^[2]
Dosage:	1, 10 and 50 mg/kg
Administration:	Intravenous injection; once daily for 3 days
Result:	Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg.

Clinical Trial

CAS 号

1129435-60-4

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.